Ikena Oncology Stock Forecast, Price & News

Wall Street analysts have given Ikena Oncology a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ikena Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Some companies that are related to Ikena Oncology include Duckhorn Portfolio (NAPA), SEMrush (SEMR), ThredUp (TDUP), Design Therapeutics (DSGN), Apria (APR), Thoma Bravo Advantage (TBA), Bioventus (BVS), Adagene (ADAG), Custom Truck One Source (CTOS), Fifth Wall Acquisition Corp. I (FWAA), Lava Therapeutics B.V. (LVTX), SVF Investment Corp. 3 (SVFC), SVF Investment Corp. 2 (SVFB), Wunong Net Technology (WNW) and Viveon Health Acquisition (VHAQ).
View all of IKNA's competitors.

(IKNA) raised $125 million in an IPO on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO.

Ikena Oncology trades on the NASDAQ under the ticker symbol "IKNA."

Ikena Oncology's quiet period expires on Wednesday, May 5th. Ikena Oncology had issued 7,812,500 shares in its IPO on March 26th. The total size of the offering was $125,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Shares of IKNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IKNA stock can currently be purchased for approximately $16.05.

Ikena Oncology has a market capitalization of $555.14 million.